Shares are through the roof as the company revealed the results of its ovarian cancer clinical trial. Needless to say, it was incredibly positive.
Prima Biomed’s Phase II CAN-003 trial used to treat patients with ovarian cancer showed a strong trend for improvement in overall survival for second remission patients.
The trial is working as expected and it should benefit ovarian cancer patients in the short term as well as the long term.
PBMD stock is up close to 260% today.